Kyle B Walsh1, Kimberly Hart2, Susan Roll2, Matthew Sperling2, Dusten Unruh3, W Sean Davidson4, Christopher J Lindsell2, Opeolu Adeoye5. 1. University of Cincinnati Neuroscience Institute, Cincinnati, Ohio; Department of Emergency Medicine, University of Cincinnati, Cincinnati, Ohio. Electronic address: walshk4@ucmail.uc.edu. 2. Department of Emergency Medicine, University of Cincinnati, Cincinnati, Ohio. 3. Division of Hematology Oncology, Department of Internal Medicine, University of Cincinnati, Cincinnati, Ohio. 4. Center for Lipid and Arteriosclerosis Science, University of Cincinnati, Cincinnati, Ohio. 5. University of Cincinnati Neuroscience Institute, Cincinnati, Ohio; Department of Emergency Medicine, University of Cincinnati, Cincinnati, Ohio; Department of Neurosurgery, University of Cincinnati, Cincinnati, Ohio.
Abstract
BACKGROUND: Blood biomarkers for ischemic and hemorrhagic stroke diagnosis remain elusive. Recent investigations suggested that apolipoprotein (Apo), matrix metalloproteinase (MMP), and paraoxonase-1 may be associated with stroke. We hypothesized that Apo A-I, Apo C-I, Apo C-III, MMP-3, MMP-9, and paraoxonase-1 are differentially expressed in ischemic stroke, hemorrhagic stroke, and controls. METHODS: In a single-center prospective observational study, consecutive stroke cases were enrolled if blood samples were obtainable within 12 hours of symptom onset. Age- (±5 years), race-, and sex-matched controls were recruited. Multiplex assays were used to measure protein levels. The Wilcoxon signed-rank test and the Mann-Whitney U-test were used to compare biomarker values between ischemic stroke patients and controls, hemorrhagic stroke patients and controls, and ischemic and hemorrhagic stroke patients. The 95% confidence intervals (CIs) for the difference of 2 medians were calculated. RESULTS: Fourteen ischemic stroke case-control pairs and 23 intracerebral hemorrhage (ICH) case-control pairs were enrolled. Median Apo A-I levels were lower in ischemic stroke cases versus controls (140 mg/dL versus 175 mg/dL, difference of 35 mg/dL, 95% CI -54 to -16) and in ischemic stroke versus ICH cases (140 mg/dL versus 180 mg/dL, difference of 40 mg/dL, 95% CI -57 to -23). Median paraoxonase-1 was lower in ischemic stroke cases than in both ICH cases and matched controls. Median Apo C-I was slightly lower in ischemic stroke cases than in ICH cases. There were no differences between groups for MMP-3, MMP-9, and Apo C-III. CONCLUSION: Apo A-I and paraoxonase-1 levels may be clinically useful for ischemic stroke diagnosis and for differentiating between ischemic and hemorrhagic strokes.
BACKGROUND: Blood biomarkers for ischemic and hemorrhagic stroke diagnosis remain elusive. Recent investigations suggested that apolipoprotein (Apo), matrix metalloproteinase (MMP), and paraoxonase-1 may be associated with stroke. We hypothesized that Apo A-I, Apo C-I, Apo C-III, MMP-3, MMP-9, and paraoxonase-1 are differentially expressed in ischemic stroke, hemorrhagic stroke, and controls. METHODS: In a single-center prospective observational study, consecutive stroke cases were enrolled if blood samples were obtainable within 12 hours of symptom onset. Age- (±5 years), race-, and sex-matched controls were recruited. Multiplex assays were used to measure protein levels. The Wilcoxon signed-rank test and the Mann-Whitney U-test were used to compare biomarker values between ischemic strokepatients and controls, hemorrhagic strokepatients and controls, and ischemic and hemorrhagic strokepatients. The 95% confidence intervals (CIs) for the difference of 2 medians were calculated. RESULTS: Fourteen ischemic stroke case-control pairs and 23 intracerebral hemorrhage (ICH) case-control pairs were enrolled. Median Apo A-I levels were lower in ischemic stroke cases versus controls (140 mg/dL versus 175 mg/dL, difference of 35 mg/dL, 95% CI -54 to -16) and in ischemic stroke versus ICH cases (140 mg/dL versus 180 mg/dL, difference of 40 mg/dL, 95% CI -57 to -23). Median paraoxonase-1 was lower in ischemic stroke cases than in both ICH cases and matched controls. Median Apo C-I was slightly lower in ischemic stroke cases than in ICH cases. There were no differences between groups for MMP-3, MMP-9, and Apo C-III. CONCLUSION:Apo A-I and paraoxonase-1 levels may be clinically useful for ischemic stroke diagnosis and for differentiating between ischemic and hemorrhagic strokes.
Authors: C E Furlong; S M Suzuki; R C Stevens; J Marsillach; R J Richter; G P Jarvik; H Checkoway; A Samii; L G Costa; A Griffith; J W Roberts; D Yearout; C P Zabetian Journal: Chem Biol Interact Date: 2010-03-23 Impact factor: 5.192
Authors: Mary F Lopez; David A Sarracino; Amol Prakash; Michael Athanas; Bryan Krastins; Taha Rezai; Jennifer N Sutton; Scott Peterman; Oksana Gvozdyak; Sherry Chou; Eng Lo; Ferdinand Buonanno; MingMing Ning Journal: Proteomics Clin Appl Date: 2012-04 Impact factor: 3.494
Authors: Eloy Cuadrado; Anna Rosell; Anna Penalba; Mark Slevin; José Alvarez-Sabín; Arantxa Ortega-Aznar; Joan Montaner Journal: J Proteome Res Date: 2009-06 Impact factor: 4.466
Authors: Koustubh Ranade; Todd G Kirchgessner; Olga A Iakoubova; James J Devlin; Terrye DelMonte; Priya Vishnupad; Lester Hui; Zenta Tsuchihashi; Frank M Sacks; Marc S Sabatine; Eugene Braunwald; Thomas J White; Peter M Shaw; Nicholas C Dracopoli Journal: Stroke Date: 2005-10-20 Impact factor: 7.914
Authors: No Soo Kim; Kyungwon Kang; Min Ho Cha; Bong-Joo Kang; Jinseok Moon; Byoung Kab Kang; Byeong-Chan Yu; Yoon-Sik Kim; Sun Mi Choi; Ok-Sun Bang Journal: Biochem Biophys Res Commun Date: 2007-10-04 Impact factor: 3.575
Authors: Marie Dagonnier; Geoffrey A Donnan; Stephen M Davis; Helen M Dewey; David W Howells Journal: Front Neurol Date: 2021-02-05 Impact factor: 4.003